| abstract |
The invention relates to a group of novel piperazine and piperidine derivatives having interesting pharmacological properties. The compounds have the general formula (a) (see formula I) wherein - R1 is hydrogen or fluoro, - R' is H or C1-4-alkyl, R2 is H, C1-4-alkyl or an oxo group, or R' and R2 together represent a bond, - R" is H or C1-4-alkyl , and the dotted lines can represent a single or double bond; - p has the value 0-2, - Y represents C, O, N or S, - T represent N or C, - R3 and R4 independently are hydrogen or C1-4-alkyl, - n has the value 1 or 2, - Q is a group of the formula -CH2-C(R5R6)-Z-R7 wherein R5 and R6 represent H or C1-7alkyl, C1-3-alkylphenyl, Z represents -C(R6R9)-O-, -C(R8R9)-C(=O)-, -C(R8R9)-C (=NOR10)-, -NH-C(=O)- or -O-CH2-, wherein R8 - R10 represent H or C1-4-alkyl, and R7 is a 5- or 6-membered cyclic group, aromatic group or hetero-aromatic group, or the 1- or 2-adamantyl group, which group R7 can be substituted with O-C1-4-alkyl, CN, halogen or C-1-4-alkyl, with the proviso that R 7 cannot be 1-alkylcycloalkyl, and that compounds wherein Z is the group-NH-C(=0)- and R5=R6=H, T is nitrogen, and the bicylic group is 1,4-benzoxazin-8-yl, quinoxalin-5-yl, quinolin-5-yl, indol-4-yl, benzoxazol-7-yl, benzimidazol-4-yl, benzothiazol-7-yl are not included, and salts thereof. These compounds have high affinity for both the dopamine D2 receptors and serotonine 5-HT1A receptors. |